CAMP - NASDAQ

CAMP4 Therapeutics Corporation

CAMP·NASDAQ

$4.24

+1.7%

HealthcareBiotechnology

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$90.06M

EPS-2.6500

P/E Ratio-1.60

Earnings Date08/13/2026

-29.55M

Operating Cash Flow

-35%

3Y-23.0%

5Y-203.0%

10Y-215.0%

-243.00K

Investing Cash Flow

-45%

3Y-94.0%

5Y-98.0%

10Y-99.0%

75.89M

Financing Cash Flow

3Y-24.0%

5Y-378.0%

10Y-394.0%

CAMP4 Therapeutics Corporation Cash Conversion Engine

CAMP · NASDAQ

FCF Components

Net Income-80.40M

Depreciation & Amortization1.64M

Stock-Based Compensation4.00M

Change in Working Capital13.01M

Others32.20M

Capital Expenditures-279.00K

Free Cash Flow-29.83M

Cash Flow Quality Analysis

FCF Conversion Rate

37.1%

Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.

CapEx Intensity

-0.9%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

+35.2%

Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.

Working Capital Impact

+$13.01M

Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.

CAMP4 Therapeutics Corporation Cash Flow Statement

CAMP • NASDAQ

CAMP4 Therapeutics Corporation Cash Flow Statement	Dec 2025	Dec 2024	Dec 2023	Feb 2023	Feb 2022	Feb 2021	Feb 2020	Feb 2019	Feb 2018	Feb 2017	Feb 2016	Feb 2015	Feb 2014	Feb 2013	Feb 2012	Feb 2011	Feb 2010	Feb 2009	Mar 2008	Mar 2007
OPERATING ACTIVITIES
Net Income	-80.4M	-51.8M	-49.3M	-44.2M	-28M	-56.3M	-51.6M	18.4M	16.6M	-7.2M	16.9M	16.5M	11.8M	44.6M	5.2M	-3.3M	-10.9M	-49.7M	-84.1M	-31.2M
Depreciation & Amortization	1.6M	1.7M	1.7M	878K	22.8M	22M	23.3M	20M	23M	23.5M	10.2M	9.4M	8.1M	2.8M	2.4M	3.1M	2.5M	6.5M	9.7M	6.9M
Change in Deferred Taxes	0.0	0.0	0.0	0.0	0.0	0.0	18.6M	-1.2M	6.4M	-2.3M	4.1M	7.9M	5.9M	-29.2M	0.0	807K	39K	3.4M	-20.8M	1.5M
Stock-Based Compensation	4M	4M	2.9M	1.4M	11.3M	11.4M	10.7M	11M	9.3M	7.8M	5.9M	4.1M	2.9M	2.9M	2.4M	2.1M	2M	1.3M	0.0	0.0
Other Non-Cash Items	32.2M	2.4M	705K	3M	-11.9M	40.6M	9.1M	11.9M	7.5M	7M	5.1M	247K	339K	411K	19K	-20K	104K	0.0	73.8M	38.4M
Change in Working Capital	13M	-1.9M	-154K	373K	1.6M	11M	-11.9M	-22.3M	2.3M	-5.7M	5.7M	-9.5M	-6.3M	-4.9M	825K	-1.8M	7.7M	7.5M	19.1M	1M
Cash from Operating Activities	-29.6M	-45.6M	-44.2M	-38.5M	-4.2M	28.6M	11.5M	47.7M	66.9M	25.8M	47.4M	28.6M	22.8M	16.6M	12.4M	857K	2.5M	13.8M	-1.5M	16.7M
INVESTING ACTIVITIES
Investments in Property, Plant, and Equipment	-279K	-441K	-678K	-4M	-13.3M	-11.4M	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	-1.4M	-2.8M
Acquisitions, Net	(36K)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	-60.7M	-13M	(0.0)	-117M	-7.7M	(0.0)	-53M	-1M	(0.0)	(0.0)	(0.0)	-887K	-28.1M	-50.5M
Purchase of Investments	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	-6.3M	-19.5M	-50.4M	-38.1M	-32.4M	-78.5M	-1.2M	-9M	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Sale/Maturity of Investments	0.0	0.0	0.0	0.0	0.0	6.3M	37.1M	56.4M	22.4M	114.4M	72M	15.1M	0.0	0.0	566K	0.0	992K	0.0	1M	0.0
Other Investing Items	0.0	0.0	0.0	0.0	5.7M	-2.3M	-366K	-2.7M	-2.4M	-2.6M	-110K	-55K	-71K	454K	0.0	428K	289K	277K	0.0	240K
Cash from Investing Activities	-243K	-441K	-678K	-4M	-7.6M	-13.7M	-65.7M	-21.8M	-26.5M	-45.6M	-90.7M	-8.7M	-64.2M	-2.4M	-510K	-785K	(215K)	-1.4M	-24M	-53.1M
FINANCING ACTIVITIES
Net Issuance of Common Stock	61.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Issuance of Debt	-208K	-824K	116K	-93K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Share Repurchases	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	-49M	(0.0)	-25M	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Other Financing Items	14.9M	72.5M	185K	100.3M	-2.6M	-27.3M	-2M	-28.9M	-2.6M	-1.8M	-23.3M	-3.1M	-3.1M	-2.6M	-1.1M	-405K	-544K	0.0	0.0	496K
Cash from Financing Activities	75.9M	71.7M	301K	100.2M	-2.6M	-27.3M	-94.8M	98.5M	-2.3M	-25.8M	148.5M	-5M	-2.5M	43.3M	-10.6M	1.2M	-6.8M	-11.5M	-6.5M	28.5M
CASH FLOW SUMMARY
Effect of Foreign Exchange Rates	0.0	0.0	0.0	25.6M	-965K	-355K	-122K	-553K	718K	-73K	0.0	0.0	0.0	0.0	0.0	0.0	139K	-542K	1.1M	-330K
Net Change in Cash	46.1M	25.7M	-44.5M	83.2M	-15.4M	-12.8M	-149.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash at Beginning of Period	65.7M	40M	84.5M	26.9M	94.6M	107.4M	256.5M	132.6M	93.7M	139.4M	34.2M	19.2M	63.1M	5.6M	4.2M	3M	6.9M	6.6M	37.5M	45.8M
Cash at End of Period	111.8M	65.7M	40M	110.1M	79.2M	94.6M	107.4M	256.5M	132.6M	93.7M	139.4M	34.2M	19.2M	63.1M	5.6M	4.2M	3M	6.9M	6.6M	37.5M
Free Cash Flow	-29.8M	-46M	-44.8M	-42.6M	-17.5M	17.2M	-9.8M	35.7M	58.6M	17.8M	43.1M	21.2M	20.7M	14.7M	11.4M	-388K	1.4M	12.9M	-2.8M	13.9M

SEC Filings

CAMP - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 14, 2026	May 14, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 23, 2026	June 10, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 24, 2026	March 18, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 05, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 05, 2026	March 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 09, 2026	January 09, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 23, 2025	December 22, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 18, 2025	December 17, 2025	2025	View Filing

Showing 1 to 10 of 34 filings

Related Guides

Blog Categories

Continue your CAMP research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.